Therawis Diagnostics GmbH is a privately held oncology-focused company with offices located in Munich, Germany, and was founded together with clinicians and scientists of the Technical University of Munich in September 2015. Therawis Diagnostics GmbH develops and aims to commercialize a comprehensive portfolio of predictive diagnostics to guide the optimal therapy for breast cancer patients.

These predictive assays will help to address unmet medical needs and major challenges in breast cancer therapy:

  • To predict whether a patient will respond to standard-of-care systemic cancer therapy and if not

  • to switch to an alternative cancer treatment option